Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754320 | 0.94 | — | — | |
| SCHEMBL25754329 | 0.90 | PAOX (0.38) | HDAC6PAOXMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25754318 | 0.90 | HDAC6 (0.41) | HDAC6PAOXMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25754338 | 0.87 | CYP1A2 (0.34) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25754211 | 0.85 | CES2 (0.38) | — | |
| SCHEMBL25754330 | 0.82 | MAOA (0.34) | HDAC6 | |
| SCHEMBL25754333 | 0.82 | KDM4E (0.42) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25754343 | 0.81 | SAT1 (0.37) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25754209 | 0.79 | CES2 (0.38) | PAOX | |
| SCHEMBL25754217 | 0.77 | CES2 (0.37) | PAOXALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | HDAC6 636/4885PAOX 4139/4885ALDH1A1 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.